Inex Pharmaceuticals Corporation

Inex Pharmaceuticals Corporation

INEX is a Canadian biopharmaceutical company developing and
commercializing proprietary drugs and drug delivery systems to
improve the treatment of cancer. INEX's strategy has been to
develop technology capable of making anti-cancer drugs more
effective and reduce their side-effects, thus giving these drugs
a competitive advantage in the marketplace. The basic approach
has been to encapsulate the drugs in a lipid envelope that is
carried through the bloodstream and delivered to disease sites
where the drugs are released to carry out their therapeutic
action.

The delivery technology, called Transmembrane Carrier
System (TCS), has led to the development of INEX's lead
product, Onco TCS. Onco TCS has completed a pivotal Phase II/III
clinical trial at leading medical centers across North America
as a treatment for relapsed aggressive non-Hodgkin's lymphoma.
Onco TCS is also being evaluated in nine additional Phase II
clinical trials for the treatment of small cell lung cancer,
Hodgkins disease, relapsed pediatric malignancies, acute
lymphoblastic leukemia and in combination therapy for both first-
line aggressive non-Hodgkins lymphoma and relapsed non-
Hodgkins lymphoma.

INEX has expanded its application of the TCS technology to the
chemotherapeutic drugs, Topotecan and Vinorelbine. Topotecan TCS
is currently being developed in partnership with
GlaxoSmithKline. The drug is expected to enter clinical trials
in 2003. Vinorelbine TCS, the third targeted chemotherapy
product is in preclinical development.

INEX is continuing its evaluation of other chemotherapeutic
drugs that have characteristics likely to be improved by
encapsulation in the TCS delivery technology.

INEX's second technology platform is called OligoVax and is
based on lipid-encapsulated oligonucleotides. When used in
combination with specific disease markers (antigens), OligoVax
has the potential to activate the immune system against various
diseases. This technology can be used to develop treatment for
cancer and infectious diseases.

INEX is traded on The Toronto Stock Exchange under the
symbol IEX.

Company Details

Year Established: 1992

Number of Employees: 187

Company Information

Ian Mortimer
Title: Vice President
Area of Responsibility: Management Executive
Telephone: (604) 419-3200
Fax: (604) 419-3201
Email: Click Here

David Main
Title: President
Area of Responsibility: Management Executive
Telephone: (604) 419-3200
Fax: (604) 419-3201
Email: Click Here

Pieter Cullis
Title: Vice President
Area of Responsibility: Management Executive
Telephone: (604) 419-3200
Fax: (604) 419-3201

Products

Oligovax

Onco Tcs
Onco TCS is a proprietary drug comprised of the widely used, off- patent, chemotherapeutic drug vincristine encapsulated in INEXs proprietary drug delivery system, Transmembrane Carrier System. Onco TCS has completed a pivotal Phase II/III clinical trial for relapsed aggressive non-Hodgkin's lymphoma and will be filing for marketing approval with the United States Food & Drug Administration in 2003.

Topotecan Tcs
Topotecan TCS is being developed with GlaxoSmithKline (GSK). The product utilizes GSKs proprietary compound, topotecan hydrochloride, as the encapsulated anticancer drug in the TCS technology. The product, currently in preclinical development, is anticipated to enter phase I clinical trials in 2003.

Vinorelbine Tcs
Vinorelbine TCS is the encapsulation of the off-patent chemotherapeutic drug, vinorelbine, in the TCS technology. The product is currently in preclinical development.

Services